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The mutations of the p53 gene previously represented one of several genetic changes involved in the development of
bovine leukemia virus (BLV)-induced lymphosarcoma, while the effects of these mutations on the function of p53 are
unknown. We identified four mutations of p53 gene in BLV-infected cattle with lymphosarcoma and demonstrated clearly the
existence of two functionally distinct groups of mutants: (i) the mutant forms with substitutions at codons 241 and 242, which
were mapped within an evolutionally conserved region and corresponded to the human ‘‘hot-spot’’ mutations, had completely
lost the capacities for transactivation and growth suppression and gained transdominant repression activity in p53-null
SAOS-2 cells; and (ii) the mutations at codons 206 and 207 were located outside the evolutionally conserved regions. These
mutants partially retained the capacity for transactivation and growth suppression and failed to inhibit the transactivation
activity of coexpressed wild-type p53, instead showing an enhancement of this activity. In addition, protein analysis using an
antibody specific for the mutant form revealed that the mutations at codons 206 and 242 induced a ‘‘mutant’’ conformation
of the bovine p53 proteins. Collectively, these results show that mutations of p53 gene in BLV-infected cattle with
lymphosarcoma can potentially alter its physiological function and may play an important role in BLV-induced leukemogen-
esis. © 1998 Academic Press
INTRODUCTION
Bovine leukemia virus (BLV) is an exogenous retrovi-
rus that is associated with enzootic bovine leukosis
(EBL), which is the most common neoplastic disease of
cattle. Infection by BLV can remain clinically silent, with
the host in an aleukemic state, or it can emerge as a
persistent lymphocytosis, characterized by an increased
number of normal B-lymphocytes and, more rarely, as
B-cell lymphoma in various lymph nodes after a long
latent period (Burny et al., 1988). BLV and human T-cell
leukemia/lymphoma virus type I (HTLV-I), which is the
causative agent of a highly aggressive malignant disor-
der of T-helper cells, namely, adult T-cell leukemia (ATL)
(Wong-Staal et al., 1983), constitute a unique subgroup
within the retrovirus family, being characterized by dis-
tinct genetic content, genomic organization, and strategy
for gene expression (Burny et al., 1988; Coffin, 1996).
These viruses lack a known oncogene and do not inte-
grate into preferred sites in their host cell genomes
(Kettmann et al., 1980; Deschamp et al., 1981; Seiki et al.,
1984). In addition to the involvement of the classical
structural genes of retroviruses, replication of these vi-
ruses is regulated at the transcriptional level (Sodroski et
al., 1984; Sagata et al., 1985) and at the posttranscrip-
tional level (Hidaka et al., 1988; Derse, 1988) by Tax and
Rex, respectively, which are products of their own genes.
Infection by these viruses is followed by a long latency
period, and later only a certain small proportion of in-
fected individuals rapidly develop the terminal disease.
Moreover, virus expression is latent within most infected
cells and circulating lymphocytes carry integrated provi-
ral DNA but do not produce detectable virus. Therefore,
infection with these viruses probably is not sufficient for
leukemogenesis; some additional rare events must be
involved in the leukemogenic process.
The protein encoded by the p53 tumor suppressor
gene plays a critical role in transducing a signal from
damaged DNA to genes that control the cell cycle and
apoptosis. Intrinsic to its function of p53 in this pathway
is the ability of p53, a tetrameric phosphoprotein, to bind
sequence-specifically to DNA containing the sequence
59-Pu Pu Pu C A/T T/A G Py Py Py-39 (Prives, 1994). p53
is mutated or inactivated in a high proportion of human
cancers such as tumors of the breast, colon, lung, ovary,
bladder, brain, and several other organs, and such mu-
tation plays an important role in the pathogenesis of
these cancers (Hollstein et al., 1994). In addition, se-
quence analysis has revealed that mutations in p53 are
involved in the pathogenesis of several human lymphoid
malignancies (Cheng and Haas, 1990; Gaidano et al.,
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1991; Bhatia et al., 1992; Cesarman et al., 1992; Sakashita
et al., 1992). These mutations have some characteristic
features: (a) the vast majority are clustered within the
central portions of the protein, where there are four
regions that are highly conserved among all normal
forms of p53 (amino acid residues 117–142; 171–181;
234–258; and 270–286) (Hollstein et al., 1991); (b) most of
these mutations are missense mutations and the mu-
tated proteins appear to gain the ability to accumulate
within the cells (Hinds et al., 1990); (c) many mutations
expose an epitope, normally cryptic in the p53 protein,
that is recognized by the monoclonal antibody (MAb) Pab
240 (Gannon et al., 1990); (d) mutants almost invariably
display abnormal DNA-binding, transcription-activation
properties and suppression of growth (Kern et al., 1991,
1992; Unger et al., 1992); and (e) some mutants lost
transformation suppressor function and gained dominant
transforming activity (Zambetti et al., 1992).
The molecular mechanisms underlying HTLV- and
BLV-induced leukemogenesis remain obscure. Recently,
50% of BLV-induced bovine tumors (Dequiedt et al.,
1995a; Ishiguro et al., 1997) and three of four bovine
B-cell lymphoma lines (Komori et al., 1996) were shown
to harbor missense mutations in p53. Furthermore, some
studies of T-cell malignancies have shown that the p53
gene is mutated at a frequency of 30% (Cesarman et al.,
1992) to 50% (Sakashita et al., 1992) in HTLV-1-induced
ATL. Thus, it seems likely that high frequent mutations in
the gene for p53 are involved in the process of leukemo-
genesis induced by BLV and HTLV. However, the effects
of these mutations on the physiologic functions of p53
are unclear.
In this study we found four missense mutations includ-
ing two new mutations at codons which were not re-
ported in previous studies (Dequiedt et al., 1995a; Komori
et al., 1996; Ishiguro et al., 1997), as determined by
sequencing within PCR-amplified exons 5–8 of tumor
tissues from EBL cattle. Furthermore, we generated mu-
tant p53 cDNAs by site-directed mutagenesis and at-
tempted the functional analyses of these mutant pro-
teins. Functional inactivation of p53 protein appears to
result from mutations that occur in BLV-induced lympho-
sarcoma and this system provides a good model for
studies of the mechanism of HTLV-1-induced T-cell leu-
kemogenesis.
RESULTS
Missense mutations within exons 5 through 8 of the
p53 gene in tumor tissues from BLV-infected cattle
Tumor tissues from 19 BLV-infected cattle with lympho-
sarcoma were analyzed for mutations within exons 5–8
of the bovine p53 gene. These are the regions most
frequently mutated in several types of human tumor
(Cheng and Haas, 1990; Gaidano et al., 1991; Bhatia et
al., 1992; Cesarman et al., 1992; Sakashita et al., 1992;
Hollstein et al., 1994) (Table 1). Samples of DNA from
peripheral blood lymphocytes (PBL) of 4 BLV-free normal
cattle and from normal kidneys of cows with lymphosar-
coma were used as controls. Although no mutated p53
gene was found in any of the BLV-free samples, muta-
tions were identified in tumor tissues from 4 of 19 cows
with lymphosarcoma: in cow pr2115, at codon 241 (Arg to
Trp); in cow pr2119, at codon 207 (His to Pro); in cow
pr2121, at codon 242 (Arg to Trp); and in cow pr2169, at
codon 206 (Arg to Lys). We determined whether the
missense mutations from the four samples were ho-
mozygous or heterozygous by PCR–SSCP analysis for
mutations within exons 5–8 of the p53 gene. Since the
SSCP analysis revealed an altered electrophoretic mo-
bility in the four tumor tissues, all missense mutations
were homozygous. Silent point mutations at codon 185 or
189 were found in 5 of 19 cases with lymphosarcoma and
these mutations were also observed in previous reports
(Dequiedt et al., 1995a; Ishiguro et al., 1997). Next, to
screen for mutations in p53 during the early stages of
BLV-induced pathogenesis in cattle, DNA from samples
of PBL from 3 BLV-infected but healthy cattle and DNA
from 1 BLV-infected cow with lymphocytosis were ana-
lyzed. As shown in Table 1, no mutation was detected in
exons 5–8 from 4 cows at asymptomatic stages. It
seems, therefore, that the missense mutation in the bo-
vine p53 gene is found specifically in BLV-infected cattle
with lymphosarcoma but not with asymptomatic stage,
an indication that mutations in this gene might be one of
the genetic changes involved in the development of BLV-
induced lymphosarcoma.
Comparison of sequences of the human and bovine
genes for p53
To check for a correlation between the four mutations
R206K, H207P, R241W, and R242W and the tumor-derived
mutations in human p53 gene, we isolated a cDNA clone,
KU-1Bp53 (GenBank Accession No. D84112), that con-
tained the full-length coding region of the bovine mutant
p53 gene from the BLV-induced bovine B lymphoid cell
line BLSC-KU1 and compared the predicted amino acid
sequences encoding this clone and those of the human
p53 genes, as reported by Zakut-Houri et al. (1985).
Based on their data and sequences of wild-type bovine
p53 gene from previous reports (Dequiedt et al., 1995b,
c), mutation at codon 241 corresponds to the hot-spot
arginine 248 in human p53 protein that affects direct
interactions with DNA, while mutation at codon 242 cor-
responds to the hot-spot arginine 249 in human p53
protein that affects the overall structure of the core do-
main (Prives, 1994; Cho et al., 1994) (Table 1). Missense
mutations at both codons 241 and 242 were mapped
within an evolutionally conserved region (Hollstein et al.,
1991) and were also in a domain required for sequence-
specific binding to DNA. In contrast, although the two
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remaining mutations (at codons 206 and 207) were lo-
cated outside evolutionally conserved regions of the p53
protein, both alterations were located in a domain re-
quired for sequence-specific binding to DNA.
Expression and distribution of mutant bovine p53
proteins in SAOS-2 cells
To elucidate the role of each of the mutations in the
development of lymphosarcoma induced by the BLV, we
first generated the wild-type and mutant R206K, H207P,
R241W, and R242W p53 cDNA from a KU-1Bp53 cDNA
clone, having a missense mutation at codon 252 (Asp to
Tyr; GAC to TAC), by site-directed mutagenesis using
PCR and then subcloned downstream of the SRa pro-
moter in expression vector pME18Neo.
The expression and localization of mutant p53 proteins
were examined by transiently transfected SAOS-2 cells
containing a homologous intragenic deletion of the p53
gene with each expression vector that encoded wild-type
or mutant p53 protein. To facilitate the assay, all of these
proteins were given a carboxyl-terminal Flag tag. We
performed Western blotting and immunostaining with
TABLE 1
p53 Mutations in PBL and Tumors from BLV-Free Normal Cattle and BLV-Infected Cattle with Lymphosarcoma at Various Stages
Cattle Age
Total No. of
PBL/mm3
of blood
Cells
used
Integrated BLV
proviral DNAa Codon Nucleotide
Amino acid
substitution Genotype
Codon of
human
p53
BLV-free normal cattle
273 8 4,154 PBL 2 NFc
275 9 3,976 PBL NTb NF
276 2 4,312 PBL 2 NF
278 2 4,088 PBL 2 NF
BLV-infected but clinically normal cattle
1 12 4,032 PBL 1 NF
115 10 8,448 PBL 1 NF
155 16 6,213 PBL 11 NF
BLV-infected but clinically normal cattle with lymphocytosis
4 14 7,134 PBL 111 NF
BLV-infected and lymphosarcoma cattle
pr1693 10 9,500 Tumor (kidney)d 111 185 CAG-CAA Silent NT 192
pr1697 9 15,300 Tumor (kidney) 111 NF
pr1698 8 19,700 Tumor (kidney) 111 NF
pr1701 13 28,000 Tumor (kidney) 111 NF
pr1705 9 23,500 Tumor (kidney) 111 189 CGG-CGA Silent NT 196
pr1707 7 3,900 Tumor (kidney) 111 NF
pr1717 13 12,100 Tumor (kidney) 111 185 CAG-CAA Silent NT 192
pr1720 11 5,800 Tumor (kidney) 111 NF
pr2107 7 9,482 Tumor (kidney) 11 185 CAG-CAA Silent NT 192
pr2108 3 19,295 Tumor (kidney) 111 NF
pr2115 10 12,921 Tumor (kidney) NT 241 CGG-TGG Arg-Trp Homozygous 248
pr2119 3 2,821 Tumor (kidney) NT 207 CAC-CCC His-Pro Homozygous 214
pr2121 10 1,950 Tumor (kidney) NT 242 CGG-TGG Arg-Trp Homozygous 249
pr2136 5 11,312 Tumor (kidney) NT NF
pr2137 6 11,600 Tumor (kidney) NT NF
pr2169 10 81,366 Tumor (kidney) 11 206 AGA-AAA Arg-Lys Homozygous 213
pr2175 12 8,215 Tumor (kidney) 11 185 CAG-CAA Silent NT 192
pr2196 7 41,640 Tumor (kidney) 111 NF
pr2197 4 7,750 Tumor (kidney) 11 NF
a Chromosomal DNA (10 mg) from tumor or PBL was completely digested with SacI and analyzed by Southern blot analysis using, as a probe, a
32P-labeled 6.9-kb EcoRI–SalI fragment of the BLV proviral DNA clone. Intensity of band: (2) none; (1) slight; (11) moderate; (111) marked.
b NT, Not tested.
c NF, Not found.
d Kidneys of cows with lymphosarcoma were used as control.
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anti-Flag MAb M2. Although the expression levels of two
mutant proteins, R241W and R242W, were four- to fivefold
lower than that of wild-type p53 protein in SAOS-2 cells,
the other two mutant proteins, R206K and H207P, were
FIG. 1. Expression and localization of mutant p53 proteins in SAOS-2
cells. (A) Western blotting of mutant p53 proteins. Cells were cotransfected
with 30 mg of the expression vector pME18Neo that encoded a carboxyl-
terminal Flag-tagged wild-type protein (lane 2), R206K (lane 3), H207P (lane
4), R241W (lane 5), R242W (lane 6) mutant proteins, or pME18Neo (lane 1)
and 5 mg of pSV-b-Galactosidase plasmid. Transfected cells were split at
40 h after transfection, a fraction was taken for b-Gal assay, and the rest
was lysed. Lysates containing equal b-galactosidase activity were sub-
jected to Western blotting with anti-Flag MAb M2. Positions of the protein
molecular weight markers and the p53 protein are indicated by the arrows.
(B) Immunofluorescent localization of mutant p53 proteins. Cells were
transfected with 10 mg of pME18Neo (a), Flag-tagged wild-type (b), R206K
(c), H207P (d), R241W (e), and R242W (f) p53 expression plasmid by
electroporation method. At 24 h posttransfection, cells were stained with
anti-Flag MAb M2 followed by a FITC-conjugated F(ab9)2 fragment of rabbit
anti-mouse IgG 1 A 1 M (H 1 L).
FIG. 2. Transactivation function and transdominance repression of
mutant p53 proteins in SAOS-2 cells. (A) Transcriptional activity was
measured by cotransfection by lipofection into SAOS-2 cells with 0.5 mg
(lanes 2, 5, 8, 11, 14, and 17), 1 mg (lanes 3, 6, 9, 12, 15, and 18), and 2.5
mg (lanes 4, 7, 10, 13, 16, and 19) of wild-type (lanes 5–7), mutants
R206K (lanes 8–10), H207P (lanes 11–13), R241W (lanes 14–16), and
R242W (lanes 17–19) expression plasmids or of pME18Neo (lanes 2–4),
plus 2 mg of a firefly luciferase reporter plasmid pGVP-FA5 which
contained 11 repeats of the p53-binding DNA sequence. The extent of
transactivation (-fold) was calculated by comparing the transcriptional
activity derived from each expression plasmid to that without expres-
sion plasmid. Each value represents the average obtained from two
independent experiments. (B) Cells were cotransfected with 0.3 mg of
wild-type p53 expression plasmid, 1.5 mg of reporter plasmid pGVP-
FA5, and the indicated amounts (0 to 1.2 mg) of wild-type or each mutant
p53 expression plasmid. The results represent the mean of two inde-
pendent experiments.
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specifically expressed at levels similar to that of wild-
type p53 (Fig. 1A). As shown in Fig. 1B, all SAOS-2 cells
transfected with each p53 expression plasmid had nu-
clear staining at levels comparable to the wild-type p53
level, while a control transfection with a pME18Neo ex-
pression vector was negative.
Transactivation functions and transdominant
transcriptional repression of mutant bovine p53
proteins in SAOS-2 cells
To determine the transactivating activity of the bovine
mutant p53 proteins, the reporter plasmid pGVP-FA5, which
contained the firefly gene for luciferase driven by a p53-
responsive element, Fragment A, and an expression vector
encoding bovine wild-type or mutant p53 were used to-
gether to transfect SAOS-2 cells, and the cells were as-
sayed for luciferase activity (Fig. 2A). Wild-type p53 exhib-
ited an increase of transactivating activity dependent on the
amount of transfected DNA. The mutants R241W and
R242W abolished transactivation activities for Fragment A,
while mutants R206K and H207P retained detectable activ-
ity of about 5–7% and 13–22% of that of wild-type p53
protein, respectively. Titrations of 0.5–2.5 mg of the expres-
sion vector of the mutants R206K and H207P demonstrated
a good correlation between the amount of plasmid trans-
fected and transactivation activity, while no transactivation
activity was detected for the inactive mutants R241W and
R242W in amounts up to 2.5 mg of transfected plasmid.
Thus, these experiments demonstrate that the transcrip-
tion-activation function of bovine p53 is either reduced by
mutation at codons 206 and 207 or abolished by mutation at
codons 241 and 242 (Table 3).
The transdominant transcriptional repression of the
bovine p53 mutants, which had either retained or lost the
p53 transactivating activity, were characterized by ana-
lyzing the transcriptional activity of each p53 protein in
the presence of wild-type protein. Wild-type and mutant
p53 expression vectors with the reporter plasmid pGVP-
FA5 were cotransfected into SAOS-2 cells (Fig. 2B).
Transdominance was most clearly seen for R241W. When
TABLE 2
Inhibition of Growth of SAOS-2 Cells by p53 Mutantsa
Transfected plasmid
Relative number of colonies (Experiment No.)
Averageb1 2 3
pME18Neo 450.39 (1.00)c 527.93 (1.00) 759.81 (1.00)
Wild-type 5.50 (0.01) 1.00 (0.01) 3.50 (0.01) 0.01
R206K 363.05 (0.81) 226.00 (0.43) 380.53 (0.50) 0.57
H207P 190.15 (0.42) 172.82 (0.33) 186.06 (0.24) 0.33
R241W 592.97 (1.32) 518.32 (0.98) 841.63 (1.11) 1.13
R242W 418.32 (0.93) 552.08 (1.05) 509.00 (0.66) 0.88
a Cells (8 3 106) were cotransfected with 10 mg of the indicated p53 plasmids with 2 mg of pSV-b-Galactosidase plasmid. At 24 h post-transfection,
cells were cultured in the presence of 800 mg of G418 per ml. The data shown present the relative number of drug-resistant colonies counted 3 weeks
after transfection. Relative number was calculated as raw number of colonies/b-Gal activity.
b The average of the three values determined for each plasmid is presented in the last column.
c Numbers in parentheses represent the calculated ratio of relative colony number relative to the relative number scored on the empty vector control
plate.
TABLE 3
Summary of the Functional and Conformational Assays of Wild-Type and Mutant Bovine p53 Proteins
Classification Mutant Distribution
Activitya of
Conformational
changebTransactivation
Transdominant
repression
Growth
arrest
I R206K Nucleus 1 2 1 11
H207P Nucleus 1 2 1 NDc
II R241W Nucleus 2 11 2 6
R242W Nucleus 2 1 2 11
Wild-type Nucleus 111 — 111 2
a Intensity of activities: (2) none; (1) slight; (11) moderate; (111) marked.
b Reactivity with Pab 240 in immunoprecipitation: (2) none; (1) weak; (11) strong.
c ND, Not determined.
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equal amounts of wild-type and R241W mutant p53 ex-
pression vectors were used, the luciferase activity de-
creased by approximately 50% compared to that
achieved by wild-type p53 alone. Increasing the ratio of
mutant p53 to wild-type p53 produced a 50 to 80% re-
duction. In addition to the R241W mutant, a weak trans-
dominantly repressive effect was observed for R242W. It
was clear, therefore, that the two tumor-derived bovine
p53 mutants that had completely lost sequence-specific
transactivating activity gained transdominant repression
activity. In contrast, the two other weak transactivation-
positive mutants, R206K and H207P, did not show the
repressive effect, rather showing a weakly transactivat-
ing effect. When additional wild-type p53 expression
vector was substituted for mutant p53 expression vector
in the cotransfection experiment, luciferase activity in-
creased rather than decreased, as expected. The
present findings also confirm that the bovine mutants
observed in this study can be separated into two types of
transactivation function: transdominantly repressing mu-
tant (R241W and R242W) and weakly transactivating mu-
tant (R206K and H207P) (Table 3).
Inhibition of SAOS-2 growth by mutant bovine p53
proteins
To gain insight into the growth arrest activity of bovine
mutant p53 proteins, SAOS-2 cells transfected with wild-
type or mutant p53 expression plasmid which contained
a neomycin resistance marker were selected with G418
and then surviving colonies counted to assess the
growth-inhibitory effect of each of the proteins (Table 2).
Mutants R241W and R242W, with no evidence of trans-
activating activity, also lacked efficient growth suppres-
sion function in SAOS-2 cells. On the other hand, mutants
R206K and H207P retained growth suppression activity,
although they were less efficient than wild-type p53 pro-
tein (43–80% and 25–42%, respectively, for R206K and
H207P). No consistent difference was observed in the
sizes of colonies obtained following transfection of the
various p53 mutants. Analysis of bovine p53 mutants
revealed that, like the human p53 (Crook et al., 1994;
Pietenpol et al., 1994), the ability to transactivate a p53
responsive promoter was well correlated with the ability
to suppress the growth of SAOS-2 cells.
Conformational analysis of the mutant bovine p53
proteins
Since the abnormal transcriptional activation proper-
ties of tumor-derived p53 mutants are correlated with
their conformational flexibility (Halazonetis and Kandil,
1993; Rolley et al., 1995), the mutation-induced changes
in conformation were investigated by immunoprecipita-
tion with p53-specific MAb Pab 240: (i) an antibody that is
‘‘mutant’’-specific in so far as it does not immunoprecipi-
tate native wild-type p53; (ii) the mutant forms affecting
the overall structure of the core but not affecting direct
interactions with DNA are more reactive with this MAb;
(iii) its epitope maps to residues 213–217 of human p53
protein; and (iv) this MAb reacts with not only human,
mouse, rat, hamster, and chicken p53 protein but also
with bovine p53 protein in immunoblots (Cook and Mil-
ner, 1990; Gannon et al., 1990; Stephen and Lane, 1992;
Crook et al., 1994; Prives, 1994).
We first examined the reactivity of Pab 240 MAb with
bovine wild-type and mutant R206K, R241W, and R242W
p53 proteins when they had been denatured. Individual
wild-type and mutant cDNAs were transfected into
SAOS-2 cells and the expression of p53 proteins was
examined by Western blot analysis. However, the H207P
protein was excluded from further experiments since the
epitope for Pab 240 MAb had been mapped to amino
acids 206–211 of bovine p53 protein containing a codon
substituted in H207P, and the Pab 240 MAb could not
FIG. 3. Characterization of mutant p53 proteins by Western blotting
and immunoprecipitation with anti-p53 MAb Pab 240. (A) SAOS-2 cells
were transfected with 30 mg of expression plasmids for wild-type
protein (lane 2), the R206K (lane 3), R241W (lane 4), or R242W (lane 5)
mutant protein, or pME18Neo (lane 1). Forty micrograms of protein in
nuclear extracts prepared from the transfected cells was subjected to
SDS–PAGE on a 10% polyacrylamide gel, and then proteins were
transferred and immunoblotted with MAb Pab 240. (B) Lysates of
L-[35S]methionine-labeled SAOS-2 cells that had been transfected with
expression plasmids for wild-type protein (lane 7), the R206K (lane 8),
R241W (lane 9), or R242W (lane 10) mutant protein, or pME18Neo (lane
6) were immunoprecipitated by Pab 240 MAb and subjected to SDS–
PAGE on a 10% polyacrylamide gel with subsequent autoradiography.
Positions of the protein molecular weight markers and the p53 protein
are indicated by arrows.
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recognize H207P p53 protein that had been translated in
vitro and that transiently expressed in SAOS-2 cells by
Western blot analysis (data not shown). As shown in Fig.
3A, strongly immunoreactive p53 proteins were specifi-
cally detected in nuclear lysates from cells transfected
with wild-type, R206K, R241W, and R242W constructs,
while the pME18Neo vector-transfected cells gave no
signal. Next, individual constructs were used to transfect
SAOS-2 cells and each set of cells was metabolically
labeled with [35S]methionine. Immunoprecipitates with
Pab 240 MAb were separated on a 10% SDS–polyacryl-
amide gel and then the 35S-labeled p53 proteins were
detected by autoradiography. Although the p53 mutant
proteins were immunoprecipitated in transfectants with
the R206K, R241W, and R242W constructs, the intensity of
the band immunoprecipitated in a transfectant with
R241W was significantly lower compared with those in
transfectants with R206K and R242W (Fig. 3B). In con-
trast, the wild-type p53 protein was not immunoprecipi-
tated with Pab 240 MAb. These results indicated that the
mutations R206K and R242W induced a ‘‘mutant’’ confor-
mation of the bovine p53 protein (Table 3).
DISCUSSION
The work presented here significantly indicates that
the mutations at codons 206, 207, 241, and 242, which
were identified in BLV-induced lymphosarcoma, may po-
tentially alter the wild-type function of bovine p53 protein,
including the conformation and transactivator and
growth suppressor activities, and then cause lymphosar-
coma. Our result also shows that the substitutions which
map either within or outside the evolutionally conserved
regions may cause distinct effects on the major proper-
ties of bovine p53. Previous studies reported that the
missense mutations of p53 gene were found in 50% of
BLV-induced tumors (Dequiedt et al., 1995a; Ishiguro et
al., 1997) and, in addition, occurred at a higher frequency
in BLV-induced tumors than in blood samples from BLV-
infected cattle with persistent lymphocytosis (50 vs 15%)
(Dequiedt et al., 1995a). Furthermore, since it has been
postulated that BLV is closely related to HTLV-I, it is also
of interest that the p53 gene is mutated at a frequency of
30–50% in ATL (Cesarman et al., 1992; Sakashita et al.,
1992). In contrast, we found a much lower mutation rate
of p53 (21.1%) than that of the above-cited reports. This
difference may be due to the fact that we examined only
exons 5 to 8 of the p53 gene, whereas the other reports
utilized all exons. Thus, it appeared that the p53 point
mutations were one of the critical events leading from
the asymptomatic stage to the lymphoma stage in ATL/
EBL. However, the effect of these mutations on the phys-
iological functions of p53 were unclear. Since a lympho-
sarcoma appears after a latency period of 1 to 8 years in
less than 5% of BLV-infected animals (Burny et al., 1988),
infection with BLV is probably insufficient for leukemo-
genesis; other secondary mutations are probably re-
quired for transformation. Therefore, our present results
and the findings in previous reports clearly conclude that
the loss of wild-type function of p53 protein induced by
these mutations appears to be an important step in the
progression of BLV-induced lymphosarcoma, as well as
in some types of human cancer. Thus, it is a first report
in cattle that the point mutations of p53 lead an abnor-
mality of its function.
The mutations at codons 206 (Arg to Lys) and 207 (His
to Pro) map outside regions of the protein that have been
highly conserved during evolution and are also new
sites, which differ from amino acids as reported previ-
ously (Dequiedt et al., 1995a; Ishiguro et al., 1997). A
human tumor-derived mutation at codon 214, corre-
sponding to a substitution at codon 207 in the bovine
p53, is rarely involved in human malignancies (Cho et al.,
1994). By contrast, missense and nonsense mutations at
codon 213 of the human p53 protein, which correspond
to a substitution at codon 206, have often been found in
B- and T-cell human lymphoid malignancies (Cheng and
Haas, 1990). In Burkitt’s lymphoma in particular, codon
213 appears to be mutated as frequently as codon 248
(Farrell et al., 1991; Gaidano et al., 1991; Bhatia et al.,
1992). In contrast to the two mutations discussed above,
the missense mutation at codon 242 (Arg to Trp), located
within the central portion of the bovine p53 protein, has
been highly conserved during evolution. Dequiedt et al.
(1995a) also showed that p53 from one bovine had his-
tidine instead of arginine at position 242 in a BLV-in-
duced bovine tumor. This residue corresponds to argi-
nine 249, which is one of six mutational hot spots in
human p53 and the site of frequent mutations in liver
cancers from southern China and southern Africa, where
there is a high incidence of hepatitis B virus and frequent
exposure to aflatoxin B (Bressac et al., 1991; Hsu et al.,
1991). Likewise, the missense mutation at codon 241
(Arg to Trp) was mapped within the evolutionally con-
served regions and corresponded to arginine 248 in
human p53, which is the most frequently mutated overall.
As well as position 242, an amino acid substitution at
position 241 was also observed in BLV-induced cattle
with lymphosarcoma (Ishiguro et al., 1997).
According to the functions and properties of the bovine
mutant p53 proteins characterized by luciferase assay,
immunoprecipitation with the Pab 240 MAb, and growth
suppression, the four missense mutations in bovine p53
found in this study can be classified into two types (Table
3). (1) The first type consists of mutations at codons 241
and 242, which map within a highly conserved region of
the p53 protein. The mutants R241W and R242W had lost
both transcription-activation activity and growth suppres-
sion function in the human p53-null SAOS-2 cell line;
both mutants also had transdominant effects over wild-
type function. The dominant-negative effect of mutant
p53 proteins is caused by oligomerization with wild-type
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p53 protein and results in an inhibition of the wild-type
ability to bind DNA and activate transcription. The crystal
structure of a p53 core-DNA complex (Cho et al., 1994)
indicates that there are two classes of naturally occur-
ring mutations in human p53: mutations in the first class
interfere directly with contacts between protein-DNA
phosphate or base contacts, while those in the second
class disrupt the structural integrity of the binding do-
main. Several human mutations have been well charac-
terized; for example, the mutation of codon 248 of human
p53, which corresponds to codon 241 of bovine p53,
belongs to the first class. The mutation of codon 249 of
human p53, on the other hand, which corresponds to
codon 242 of bovine p53, belongs to the second class.
These two classes of mutants can be distinguished by
their reactivity with the Pab 240 MAb, which is mutant-
specific in that it does not recognize native wild-type p53
(Cook and Milner, 1990; Gannon et al., 1990; Stephen and
Lane, 1992). The second class of mutants is more reac-
tive with the Pab 240 MAb than is the first class of
mutants. Indeed, the Pab 240 MAb immunoprecipitated
as a major band containing mutant R242W and a minor
band containing mutant R241W. Such evidence may sup-
port a model wherein a mutation at codon 241 or 242
results in a protein that is defective in binding to enhanc-
er-like elements: R241W effects a direct contact with
DNA; R242W induces a conformational change in the
overall structure of the core domain, and such a protein
cannot activate the transcription of genes. Such loss of
wild-type function of p53 protein induced by these mu-
tations at codons 241 and 242 appears to be an impor-
tant step in leukemogenesis. While we did not examine
the transforming potential conferred by these mutations,
these modifications could possibly contribute to the tu-
morigenic phenotype since mutants at codons 248 and
249 in the human p53 protein can act cooperatively with
the ras gene to transform primary rat embryo fibroblasts
in vitro (Hinds et al., 1990). (2) Mutations in the second
type are those at codons 206 and 207, which are located
outside regions of the protein that have been highly
conserved during evolution. R206K and H207P mutant
proteins partially retained the ability to activate transcrip-
tion and growth-inhibitory function and failed to repress
the transcriptional activity of coexpressed wild-type p53,
instead showing an enhancement of this activity. This
suggests that these mutants may be insufficient to in-
duce lymphosarcoma and may require dysfunction of the
other cellular gene products for leukemogenesis in BLV-
infected cattle. Therefore, to further clarify the relation-
ship between these mutations and BLV-induced leuke-
mogenesis, we are conducting additional pathological
examinations to differentiate the malignant behavior and
pathogenesis of tumors from individuals that showed
evidence of two different types of p53 mutation.
Our findings show that the mutation of p53 genes
occurred when the disease proceeded to lymphoma
stage and these naturally occurring mutations may po-
tentially alter the wild-type function, and in addition, of
four missense mutations, at least two mutations may be
sufficient to cause BLV-induced lymphosarcoma. How-
ever, since the other two mutants may be insufficient to
induce lymphosarcoma, it is possible that other cancer-
related genes may be related to BLV-induced lymphosar-
coma in concert with p53 mutations. Therefore, further
studies of the four missense mutations in bovine p53 in
various biological systems should prove worthwhile for a
full understanding of BLV-induced leukemogenesis.
MATERIALS AND METHODS
Samples and DNA extraction
Blood samples were obtained from four healthy cows
that were negative for BLV-specific antibodies, three BLV-
infected but clinically and hematologically normal cows,
and one BLV-infected but clinically normal cow with mod-
erate increase in lymphocytosis (Table 1). PBL were
separated from blood by the method of Miyasaka and
Trnka (1985) and total chromosomal DNA was extracted
from these cells by the method of Hughes et al. (1978).
Samples of tumors and kidneys were obtained from 19
BLV-infected cows with lymphosarcoma (Table 1) and cut
into slices about 0.5 cm in thickness and 1 cm2 in area.
They were frozen rapidly in liquid nitrogen and then
stored at 280°C. Genomic DNA was prepared from
these frozen blocks of tissue with 10% SDS and phenol–
chloroform (McKnight, 1978). BLV-infected cattle were
classified according to the previously established criteria
(Aida et al., 1993) and the genomic integration of the BLV
provirus. To detect the BLV provirus, 10 mg of total chro-
mosomal DNA was exhaustively digested with either
SacI or HindIII and analyzed by Southern blotting (Sam-
brook et al., 1989), with the 32P-labeled 6.9 kb EcoRI–SalI
fragment of BLV proviral DNA as a probe (Sagata et al.,
1983). An immunodiffusion test was performed to detect
antibodies against BLV, using the env glycoprotein gp51
and gag protein p24 of BLV as antigens.
Amplification, cloning, and characterization of the
bovine p53 genomic sequence
To amplify the bovine p53 genomic sequence by PCR, we
prepared two sets of oligonucleotide primers covering hot-
spot positions for point mutations in p53. The following
primers were used. Set I was used to amplify exons 6 and
7 and a portion of exon 5 including introns: GF, 59-GGAG-
GATCCGACGGAGGTTGTGAGGCGTTG-39; and HR, 59-AAG-
GTCGACCAGTGTGATGATGGTGAG-39. Set 2 was used to
amplify exon 8 and a portion of exon 7 including an intron:
E8-1, 59-TTTGGATCCTAACAGCTCCTGCATGGGGGG-39;
and E8-2, 59-CTCGTCGACTGCTCCTAGGGGGTGGCTC-39.
The underlined sequences show enzyme sites for BamHI
and SalI, respectively.
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Genomic DNA was dissolved in a total volume of 100
ml of 13 PCR buffer [10 mM Tris–HCl, pH 8.3, 50 mM KCl,
1.5 mM MgCl2, 0.001% (w/v) gelatin] with 0.2 mM dNTPs,
1 mM each primer, and 2.5 units of Taq polymerase
(Gene Amp Kit; Perkin–Elmer Cetus). Amplification was
achieved by 35 cycles at 94°C for 1 min, at 61°C for 2
min, and at 72°C for 2 min, followed by a 10-min exten-
sion at 72°C. Products amplified by PCR were subcloned
into the BamHI–SalI site of pBluescript II (SK1) (Strat-
agene) and the nucleotide sequences of both strands
were determined by the dideoxy chain-termination
method (Sanger et al., 1977) with a BcaBEST sequence
kit (Takara Shuzo). All mutations were reproducibly de-
tected in both sense and antisense strands from several
preparations of either two or more independently ampli-
fied DNA samples, ruling out spurious PCR-induced mu-
tation. Computer analyses were performed with the pro-
gram package from the Wisconsin Genetics Computer
Group, which included FASTA and TFASTA (Pearson and
Lipman, 1988).
The PCR–single-strand conformation polymorphism
(PCR–SSCP) analysis was performed as described pre-
viously with brief modification (Orita et al., 1989).
Isolation and characterization of cDNA of the bovine
p53 gene and site-directed mutagenesis
A cDNA library from the bovine lymphoid cell line
BLSC-KU1 (Onuma et al., 1986) was constructed in the
mammalian expression vector pCDM8, as described
previously (Aida et al., 1994). To obtain a cDNA clone that
contained the full-length coding region of a mutant bo-
vine p53 gene (KU-1Bp53), the plasmid DNA prepared
from the cDNA library was amplified by PCR using prim-
ers Bp53F1, 59-GGCTCGAGACACAACCTTCCAGGGA-39;
and Bp53R1, 59-CACTGCAGGGTCTAGCACCTGAGTCTC-
39. The sequences were derived from the 59- and 39-
flanking sequences of the ovine and bovine p53 gene
(Dequiedt et al., 1995b, c). The underlined sequences
show enzyme sites for XhoI and PstI, respectively. PCR
was done under the conditions as described for ampli-
fication of p53 genomic DNA. Amplified DNA was sub-
cloned into pBluescript II (SK1) and the nucleotide se-
quences of both strands were determined as described
for amplification of p53 genomic DNA.
To generate the cDNA for wild-type bovine p53, a
single point mutation was introduced into the KU-1Bp53
mutant gene which was subcloned into pBluescript
II(SK1) by ExSite PCR-based site-directed mutagenesis
(Stratagene) using the following oligonucleotides: wildF,
59-ATCACACTGGAAGACTCTTGTGGTA-39, and wildR, 59-
GATGGTGAGGATGGGCCGCCGGTTC-39, as primers.
The mutations R206K and H207P were created by PCR
using the wild-type bovine p53 template, the 206mF
primer, 59-TCCGGTCGTCCAAATACTCCGCGCG-39, and
the following second primers: 206mR primer, 59-ACAC-
CTTTAAACACAGTGTGGTGGT-39, for R206K; and 207mR
primer, 59-ACACCTTTAGACCCAGTGTGGTGGT-39, for
H207P. The R241W and R242W mutations were created
by PCR using the wild-type bovine template, the 242mR
primer, 59-CCATCATCACACTGGAAGACTCTTG-39, and
the following second primers: 241mF primer, 59-TGAG-
GATGGGCCGCCAGTTCATGC-39; and 242mF primer, 59-
TGAGGATGGGCCACCGGTTCATGC-39, for R242W. All
constructs described above were verified by DNA se-
quencing. All the p53 sequences in pBluescript II (SK1)
were excised as XhoI–NotI fragments and subcloned
downstream of the SRa promoter, which is composed of
simian virus 40 (SV40) early promoter and the long ter-
minal repeat (LTR) of HTLV-I (Takebe et al., 1988), in the
expression plasmid pME18Neo (Nagata et al., 1995).
To facilitate biochemical analysis of p53 proteins, wild-
type and all mutant p53 proteins were given a carboxyl-
terminal tag (Flag tag) with the following amino acids
sequence: Met-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-
COOH. All the p53 sequences were amplified by PCR
with the following oligonucleotides: FL1, 59-AACTCGAG-
GTCTGAGTCAGGCCCCTC-39, and FL2, 59-CCGATATCAT-
GGAAGAATCACAGGCA-39. The underlined sequences
show enzyme sites for XhoI and EcoRV, respectively. PCR
product was cloned into pBluescript II (SK1) containing
the Flag sequence at the XhoI–EcoRV site (Nishino et al.,
1997) and then the XhoI–EcoRI fragment containing p53
cDNA and Flag sequence was subcloned downstream of
the SRa promoter in pME18Neo.
Cell culture and transfection
The human osteosarcoma cell line SAOS-2, which had
lost the entire genomic region that included the p53
gene, was maintained in RPMI 1640 (GIBCO BRL) sup-
plemented with 10% heat-inactive fetal calf serum.
For Western blotting, immunoprecipitation, immunoflu-
orescence analysis, and stable growth assay, SAOS-2
cells (8 3 106) were transfected with 10–30 mg of each
p53 expression plasmid by electroporation using a Gene
Pulser (Bio-Rad) at 960 mF and 270 V. For luciferase
assay, SAOS-2 cells (3 3 105) were plated in 35-mm-
diameter dishes 1 day before transfection and lipofected
using the DOSPER reagent and protocol from Boehringer
Mannheim.
Western blotting
The nuclear lysate was prepared as described previ-
ously (Schreiber et al., 1989), solubilized in Laemmli’s
buffer (Laemmli, 1970), and subjected to SDS–PAGE on a
10% polyacrylamide gel. The proteins on the gel were
transferred to a polyvinylidene difluoride membrane filter
(PVDF; Millipore) and the filter was incubated in buffer
that contained anti-p53 MAb Pab 240 (Santa Cruz) (Gan-
non et al., 1990), anti-Flag MAb M2 (Eastman KODAK), or
preimmune normal mouse serum. After washing, the
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filter was incubated with sheep anti-mouse immunoglob-
ulin conjugated to horseradish peroxidase, and then
products were detected with enhanced chemilumines-
cence (ECL) detection reagents (Amersham).
Luciferase reporter gene assay
The firefly luciferase reporter plasmid pGVP-FA5,
which contained 11 repeats of the p53-binding DNA
sequence known as Fragment A, was used (Kato et al.,
1996). SAOS-2 cells were cotransfected with 0.3–2.5 mg
of each p53 expression plasmid, 1.5–2 mg of pGVP-FA5,
and 0.5 mg of pRL-SV40, which encodes Renilla lucif-
erase gene (Promega), the cells were harvested at 2
days after transfection, cell extracts were prepared in a
lysis buffer from a Dual-Luciferase Reporter Assay Sys-
tem (Promega), and firefly luciferase activity and Renilla
luciferase activity were measured with a luminometer
(TD-20/20; Turner Designs) as raw light unit (RLU). Rel-
ative firefly luciferase activity was calculated as firefly
luciferase activity/Renilla luciferase activity.
Immunofluorescence analysis
At 40 h after transfection with 10 mg of each p53 expres-
sion plasmid, SAOS-2 cells growing on coverslips in a
35-mm-diameter dish were fixed for 30 min at 4°C in PBS
containing 1% formaldehyde and then permeabilized for 5
min at 4°C in PBS containing 0.2% Triton X-100. After incu-
bation for 10 min with phosphate-buffered saline (PBS)
containing 0.1% bovine serum albumin, the coverslips were
stained with either M2 MAb or preimmune normal mouse
serum, followed by a FITC-conjugated F(ab9)2 fragment of
rabbit anti-mouse IgG 1 A 1 M (H 1 L) (Zymed Laborato-
ries Inc.). The coverslips were washed several times with
PBS and mounted on glass slides in PBS containing 90%
glycerol.
Immunoprecipitation
At 36 h after transfection with 30 mg of each p53 expres-
sion plasmid, SAOS-2 cells were split, a fraction was used
for preparation of nuclear lysate for Western blotting, and
the rest were plated (1 3 106) in 60-mm dishes and labeled
with 150 mCi/ml of L-[35S]methionine (NEN Research Prod-
ucts) for 8 h. The labeled cells were collected and lysed on
ice in 1 ml of RIPA buffer (50 mM Tris–HCl, pH 7.6, 0.15 M
NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholic acid, and 1
mM phenylmethanesulfonyl fluoride) for 30 min. The cell
lysate was clarified by centrifugation (105 g) at 4°C for 30
min, and the supernatant was subjected for immunopre-
cipitation with Pab 240 MAb or preimmune normal mouse
serum. The immunocomplexes were collected on Protein
A–Sepharose CL-4B (Pharmacia Biotech), fractionated by
SDS–PAGE on a 10% polyacrylamide gel, and visualized by
subsequent autoradiography.
Stable growth assay
SAOS-2 cells were cotransfected with 10 mg of each
p53 expression plasmid and 2 mg of pSV-b-Galactosi-
dase plasmid (Promega). Twenty-four hours after elec-
troporation, cells were split, a fraction was taken for
b-Gal assay (b-Gal Reporter Gene Assay kit; Boehringer
Mannheim), and the rest replated in 800 mg/ml G418
(GIBCO BRL) in SAOS-2 cell for growth analysis. After 3
weeks of drug selection, colonies were fixed in metha-
nol, stained with Giemsa solution, and counted. The
relative number of colonies was calculated as number of
colonies/b-Gal activity.
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